Creatinine: Laboratory Value and Significance of Renal Function

Creatinine is a metabolic end product of creatine and phosphocreatine, formed predominantly in muscle tissue and excreted in urine. Because of its relatively constant formation rate and predominantly renal elimination, serum creatinine is one of the most frequently determined laboratory values for assessing renal function. In practice, creatinine is rarely interpreted alone. The estimated glomerular filtration rate (eGFR), which is calculated using the creatinine value, age, sex, and formerly ethnicity, is more informative.

Creatinine is therefore not a drug substance in the classical sense, but an endogenous marker. Nevertheless, the value has direct therapeutic consequences: it determines the selection and dosing of many medications, the risk profile of contrast agents, the necessity of dialysis, or the use of nephroprotective therapies such as SGLT 2 inhibitors or ACE inhibitors. Anyone taking medications regularly will therefore encounter this value frequently during the course of treatment.

Formation and Significance

Creatine is formed from the amino acids glycine, arginine, and methionine in the liver, kidney, and pancreas, and transported via blood to the muscle cell. There, creatine is converted by phosphorylation to phosphocreatine, a rapidly available energy store. When energy is needed, phosphocreatine breaks down non-enzymatically to creatinine, which enters the plasma and is filtered almost completely by the glomerulus. A small degree of tubular secretion is physiological but can increase with some medications.

Since the formation rate depends on muscle mass, men on average have higher values than women. Very muscular people can permanently have elevated values without kidney disease, while older or severely malnourished patients with small muscle mass may show only moderately elevated creatinine values despite severe renal insufficiency. Precisely for this reason, assessment of serum creatinine alone without considering age, sex, and body composition is misleading.

In clinical practice, creatinine is therefore used in two derived quantities: first as eGFR according to the CKD EPI formula, which is based on population data. Second as creatinine clearance according to the Cockcroft Gault formula, which additionally considers body weight and is especially relevant for medication dose adjustment. Both values correlate but are not identical.

Clinical Application

• Assessment of renal function in chronic kidney disease, acute kidney injury, and in the course of known nephropathies
• Dose adjustment of medications with renal elimination, such as direct oral anticoagulants, antibiotics, glucose-lowering agents, antiepileptic drugs
• Risk assessment before contrast agent administration in computed tomography and angiography
• Monitoring during nephrotoxic therapies, such as aminoglycosides, vancomycin, cyclosporine, cisplatin, NSAIDs, or ACE inhibitors
• Monitoring after kidney transplantation, in combination with additional markers such as tacrolimus levels and proteinuria
• Screening in patients with diabetes, hypertension, cardiac disease, or polypharmacy

Reference Values and Determination

Serum creatinine reference range (laboratory dependent): Men approximately 0.7 to 1.2 mg per dL (62 to 106 µmol per L), women 0.5 to 1.0 mg per dL (44 to 88 µmol per L). The exact reference ranges differ depending on method and laboratory. The values stated on the laboratory report are always decisive.

eGFR (CKD EPI): Values above 90 mL per minute per 1.73 m² are considered normal in the absence of additional findings, 60 to 89 as mildly reduced, 30 to 59 as moderately reduced, 15 to 29 as severely reduced, and below 15 as end-stage renal disease. The KDIGO guideline divides chronic kidney disease into five stages (G1 to G5) plus albuminuria stages (A1 to A3).

Determination: Standard is the Jaffe method or enzymatic determination in serum. In 24-hour urine collection, endogenous creatinine clearance can be measured directly, which may be more accurate in pregnant women, very muscular, or cachectic patients. Cystatin C is an additional endogenous marker that is largely independent of muscle mass and is determined as a complementary measure in diagnostically unclear findings.

Clinical consequence according to eGFR: Many medications require dose reduction or are contraindicated at eGFR below 60. At eGFR below 30, substances such as metformin or some direct oral anticoagulants are no longer recommended at standard doses. At eGFR below 15, all medications must be critically reviewed.

Factors Influencing the Value

Elevated: true renal insufficiency, acute renal failure of all causes, pronounced muscle mass, intensive physical activity in the past 24 hours, protein-rich meal (especially meat), rhabdomyolysis, dehydration, heart failure with reduced renal perfusion, shock, postrenal stasis from urinary outflow obstruction.

Reduced: reduced muscle mass (cachexia, sarcopenia, elderly patients), pregnancy, severe liver disease, prolonged immobility with muscle atrophy, pronounced hyperhydration.

Acute changes: In acute kidney injury, creatinine rises with a delay. An increase of at least 0.3 mg per dL within 48 hours or 1.5 times the baseline value within one week defines acute kidney injury according to KDIGO. Early markers (NGAL, urine microalbumin) are beyond routine care.

Pseudoincrease: various substances can apparently increase creatinine biochemically or functionally without the actual filtration rate decreasing. Examples include cobicistat, trimethoprim, and cimetidine, which block tubular creatinine secretion.

Medications and Creatinine

• ACE inhibitors and angiotensin receptor blockers: lower intraglomerular pressure and can cause a mild creatinine increase of up to 30 percent, which is usually accepted initially. With significantly higher increases, review therapy, especially if renal artery stenosis is suspected.
• NSAIDs: inhibit renal prostaglandins, reduce perfusion, and can trigger acute kidney injury in at-risk patients.
• Aminoglycosides, vancomycin, cisplatin, cyclosporine, tacrolimus, methotrexate: nephrotoxic effects, regular monitoring required.
• SGLT 2 inhibitors: initial moderate creatinine increase, but long-term nephroprotective effect with reduced progression of kidney disease.
• Diuretics: with excessive volume reduction, prerenal deterioration of renal function with creatinine increase.
• Trimethoprim, cimetidine, dolutegravir, cobicistat: elevation of serum creatinine through blockade of tubular secretion without true functional loss.
• Contrast agents: risk of contrast-induced nephropathy, hydration before examination, possibly pause nephrotoxic comedications.

Special Notes

Pregnancy: Creatinine decreases slightly due to increased plasma volume and enhanced glomerular filtration. Values above 0.8 mg per dL during pregnancy may already indicate a relevant functional disorder.

Children: Reference ranges are age-dependent and lower than in adults. For eGFR in children, the Schwartz formula is often used, which is based on body height and creatinine.

Athletes: Permanently elevated creatinine values even without disease. It is important to include other markers (cystatin C, albuminuria, ultrasound). A creatinine increase from dietary supplements can temporarily lead to higher creatinine values.

Interpreting changes: a single value must always be assessed in context. Important are trends, hydration status, accompanying symptoms, additional laboratory values (urea, electrolytes, potassium, phosphate, albumin, urinalysis, albumin creatinine ratio).

Note on ethnic adjustment: the previously customary adjustment in US equations for patients of African descent is no longer applied in current recommendations because it caused diagnostic inequities.

You might also be interested in

• Ertugliflozin, SGLT 2 inhibitor with nephroprotective profile
• Enalapril, ACE inhibitor with moderate creatinine increase at start of therapy
• Losartan, angiotensin II receptor blocker in hypertension and nephropathy
• Heparin, anticoagulant with dose adjustment for impaired renal function
• Vancomycin, glycopeptide antibiotic with level monitoring due to nephrotoxicity

Frequently Asked Questions

Sources

• Gelbe Liste, Laboratory Values and Active Substances
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines for Chronic Kidney Disease
• KDIGO, International Guidelines for Renal Function